"A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)." by Ignacio Melero

Selected Works of Walter J. Urba, MD, PhD

Article

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

Journal of Clinical Oncology (2017)

Ignacio Melero, University of Navarra
Tara C. Gangadhar, University of Pennsylvania
Holbrook Edwin Kohrt, Stanford University
Neil Howard Segal, Memorial Sloan Kettering Cancer Center
Theodore Logan, Indiana University
Walter John Urba
F. Stephen Hodi, Harvard University
Patrick Alexander Ott, Harvard University
Jose Luis Perez-Gracia, University of Navarra
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
Aadhar Shah, Bristol-Myers Squibb
John F. Kurland, Bristol-Myers Squibb
Lewis J. Cohen, Bristol-Myers Squibb
Ronald Levy, Temple University
Jon M. Wigginton, Bristol-Myers Squibb
Stacie M. Goldberg, Memorial Sloan Kettering Cancer Center

Disciplines

Publication Date

January 30, 2017

Citation Information

Ignacio Melero, Tara C. Gangadhar, Holbrook Edwin Kohrt, Neil Howard Segal, et al.. "A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL)." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/walter-urba/97/